ZYNATAC

This brand name is authorized in Nigeria.

Active ingredients

The drug ZYNATAC contains one active pharmaceutical ingredient (API):

1	Ranitidine UNII BK76465IHM - RANITIDINE HYDROCHLORIDE
	Ranitidine is a specific rapidly acting histamine H2-antagonist. It inhibits basal and stimulated secretion of gastric acid, reducing both the volume and the acid and pepsin content of the secretion. Ranitidine has a relatively long duration of action and so a single 150 mg dose effectively suppresses gastric acid secretion for twelve hours.
	Read more about Ranitidine

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-9449	Tablet	ZYNATAC TABLETS TAB 150 mg 10 X 10	57 RNW-PP-391801 ZYNATAC TABLETS RANITIDINE USP 150MG RANITIDINE USP 150MG EXCIPIENTS, MICROCRYSTALINE CELLULOSE, CROSCARMELLOSE SODIUM, PURIFIED TALC, MAGENESSIUM STEARATE, ISOPROPYL ALCOHOL B4-9449 Drugs Imported Products 1010 Prescription Only Medicine (POM) 12/22/2023 ZMC INTERNATIONAL LIMITED., 7A NIGER STREET,KANO, KANO STATE, NIGERIA 576768789 zmcinternational18@gmail.com APEX FORMULATIONS PVT LTD, 1276, RAJPUR, ZULASAN ROAD, AHMEDABAD - MEHSANA HIGHWAY, DIST, MEHSANA GUJARAT, INDIA, India	28/02/2024

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A02BA02	Ranitidine	A Alimentary tract and metabolism → A02 Drugs for acid related disorders → A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) → A02BA H2-receptor antagonists
Discover more medicines within A02BA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	B4-9449